Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Cedar Grove Capital Management Paul Cerro | “Nektar Therapeutics ($NKTR) is a clinical biopharmaceutical firm developing rezpegaldesleukin (rezpeg) for autoimmune conditions, primarily atopic dermatitis and alopecia areata. The manager remains firmly bullish, emphasizing that recent price declines overlook valuable clinical pipeline progress and the resolution of long-standing legal overhangs. Economically, the investment thesis is backed by a substantial cash infusion following a favorable breach-of-contract verdict against Eli Lilly awarding approximately $115 million in total damages. The manager argues that market participants are neglecting rezpeg's multi-billion dollar commercial potential in atopic dermatitis, pricing the equity well below an estimated intrinsic value of over $165 per share. Catalysts include clinical data readouts scheduled for Q1 2027 and formal receipt of court damages. The primary risks involve clinical trial setbacks, development timelines spanning an extended catalyst desert, and negative sentiment among short sellers.” | BULL | Q3 2026 Oct 5, 2026 | View Pitch |
Cedar Grove Capital Management Paul Cerro | “During the quarter, we increased our positions in Nektar Therapeutics (NKTR), Abivax SA (ABVX), The Oncology Institute (TOI), and Evolv Technologies (EVLV). NKTR and ABVX had good clinical data reported, which we talk about at the end, while EVLV delivered outstanding earnings and showed that the demand and growth for weapons detection systems is alive and well. Lastly, Nektar Therapeutics released its positive alopecia areata trial data in April that showed its second indication for its Rezpeg drug could be a viable option. The stock rallied ~50% on the news but has since receded to near our original cost basis. Like ABVX, we unfortunately did not receive any benefit from positive trial data. NKTR will also need more time.” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.